6 hours ago
1
Oakozhan/iStock via Getty Images
Shares of BioXcel Therapeutics (NASDAQ:BTAI) initially climbed and then fell in the premarket on Wednesday after the New Haven, Connecticut-based biotech said its lead asset, BXCL501, reached the main goals in a Phase 3 trial.
The study named SERENITY was
© FBT Company 2025. All rights are reserved
English (US) ·